Rethinking Pre-Med: could skipping allergy drugs improve IBD treatment?
NCT ID NCT07385131
First seen Feb 03, 2026 · Last updated Apr 28, 2026 · Updated 10 times
Summary
This study looks at whether people with moderate-to-severe inflammatory bowel disease (IBD) need to take dexamethasone (a steroid) before their infliximab infusion to prevent allergic reactions. Researchers will compare patients who get the routine pre-medication with those who don't, to see if skipping it is safe and reduces side effects. The goal is to personalize care and avoid unnecessary medications. About 300 participants aged 14-80 with Crohn's disease or ulcerative colitis will be observed over their first four treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.